Key Highlights
- Expanding Drug-Delivery Platforms: Kindeva acquires Summit Biosciences, adding intranasal drug delivery to its diverse capabilities in drug-device combination products.
- Enhanced Patient Care and Experience: This acquisition aligns with Kindeva’s ambition to improve patient outcomes globally through innovative drug delivery solutions.
- Strategic Growth in Manufacturing: Summit’s FDA and EMA-approved 55,000-square-foot cGMP facility in Lexington enhances Kindeva’s global manufacturing footprint.
Source: Business Wire
Notable Quotes
- “Nasal drug delivery is becoming a preferred dosage format for a growing number of indications, as it allows users to non-invasively administer medications in an acute or emergency setting,” – Milton Boyer, CEO at Kindeva
- “Joining Kindeva strengthens our ability to deliver best-in-class nasal product development and manufacturing,” – Richard D. Cohen, Departing Chairman and CEO at Summit Biosciences
SoH's Take
The acquisition of Summit Biosciences by Kindeva Drug Delivery marks a significant milestone in the drug-device combination market. Kindeva’s strategic decision to expand into nasal drug delivery through this acquisition showcases their commitment to innovation and patient care. With the increasing demand for non-invasive drug delivery methods, Kindeva’s enhanced capabilities position them as a more versatile and comprehensive service provider in the biopharma sector.
The inclusion of Summit’s state-of-the-art cGMP facility not only broadens Kindeva’s manufacturing capabilities but also demonstrates their dedication to meeting stringent regulatory standards. This move is a testament to Kindeva’s vision of being a global leader in the CDMO market, offering a diverse range of solutions to improve patient outcomes and care experiences worldwide. As the industry continues to evolve, such strategic expansions are essential for companies looking to stay at the forefront of pharmaceutical innovation and manufacturing excellence.
